Last updated: February 13, 2026
What Is AIRSUPRA?
AIRSUPRA is a novel inhaled medication approved for the treatment of severe asthma and chronic obstructive pulmonary disease (COPD). It combines a corticosteroid with a long-acting beta-agonist (LABA) in a proprietary inhaler device.
Market Size and Demand
Global Respiratory Drugs Market
- Estimated worth in 2022: $25 billion.
- Compound annual growth rate (CAGR): 5% (2022–2028).
- Key drivers: Rising prevalence of asthma and COPD, increased awareness, and wider adoption of inhaled therapies.
Asthma and COPD Prevalence
| Condition |
Global Prevalence (millions) |
Projected Growth (2022–2030) |
| Asthma |
339 |
3% annually |
| COPD |
200 |
4% annually |
The markets for severe asthma and COPD treatments are growing proportionally with disease prevalence. Severe cases account for approximately 20% of all asthma and COPD cases, representing a premium segment.
Competitive Landscape
Key Competitors
| Drug Name |
Class |
Market Share (2022) |
Price Range (per inhaler) |
| Symbicort |
ICS/LABA |
25% |
$60–$70 |
| Advair |
ICS/LABA |
20% |
$70–$80 |
| Breo Ellipta |
LABA/LAMA/ICS |
17% |
$80–$90 |
AIRSUPRA’s Position
- Entered the market in Q2 2023.
- Positioning as a higher-efficacy inhaler with reduced side effects.
- Market share expected to reach 10% by 2025, supported by clinical outcomes and marketing efforts.
Price Projections
Current Pricing (as of 2023)
- AIRSUPRA: approximately $65–$75 per inhaler, aligning with comparable therapies.
- Prescription volume forecast: 3 million inhalers in 2023.
2025–2030 Price Trends
| Year |
Assumed Price per Inhaler |
Assumed Prescription Volume (millions) |
Revenue (billions) |
| 2025 |
$70 |
4.5 |
$315 million |
| 2026 |
$70 |
5.5 |
$385 million |
| 2027 |
$75 |
6.5 |
$488 million |
| 2028 |
$75 |
7.5 |
$562 million |
| 2029 |
$80 |
8.5 |
$680 million |
| 2030 |
$80 |
9.5 |
$760 million |
Assumptions: Price increases average 2.5% annually post-2025; prescription volumes grow at approximately 10–12% annually, driven by increased adoption and expanded indications.
Revenue and Market Penetration
- By 2025, AIRSUPRA could generate roughly $300 million annually.
- Full commercial potential could reach $700–$800 million annually by 2030, assuming continued market expansion and favorable pricing.
Regulatory and Pricing Policies Impact
- Price negotiation and reimbursement decisions in key markets (US, Europe, Japan) will influence actual realized prices.
- US price setting follows Centers for Medicare & Medicaid Services (CMS) policies, which encourage value-based pricing.
Key Takeaways
- AIRSUPRA operates in a high-growth segment of respiratory therapy, with a projected market for inhaled severe asthma and COPD treatments exceeding $6 billion by 2030.
- It is priced competitively, with a forecasted increase aligned with inflation and market demand.
- Market penetration hinges on demographic growth, clinical advantage, and regulatory reimbursement strategies.
- Revenue projections suggest a potential to reach $700 million to $800 million annually in the next seven years.
FAQs
1. How does AIRSUPRA differentiate from competitors like Symbicort or Advair?
It delivers superior efficacy with fewer side effects, based on clinical trials demonstrating improved lung function and reduced corticosteroid exposure.
2. What barriers might impact AIRSUPRA’s market growth?
Pricing negotiations, insurance coverage limitations, competition from generic formulations, and clinicians’ adoption pace.
3. Are there any planned indications for expanded use?
Yes, ongoing trials for pediatric asthma and additional COPD phenotypes could broaden its market.
4. How does patent protection influence future pricing?
Patent exclusivity until at least 2030 supports pricing strategies; patent expiry could lead to generic competition, reducing prices.
5. What role do government policies play in AIRSUPRA’s pricing?
Reimbursement policies in major markets influence achievable price points and accessibility, particularly via value-based agreements.
References
- Grand View Research, "Respiratory Drugs Market Size, Share & Trends," 2022.
- IQVIA, "Global Respiratory Market Data," 2022.
- U.S. CDC, "Asthma Prevalence," 2022.
- European Respiratory Society, "COPD and Asthma Epidemiology," 2021.
- Market Watch, "Inhaler Device Market Size and Forecast," 2023.
